[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Wiendl, HeinzHeinzWiendlGold, RalfRalfGoldBerger, ThomasThomasBergerDerfuss, TobiasTobiasDerfussLinker, RalfRalfLinkerMäurer, MathiasMathiasMäurerStangel, MartinMartinStangelAktas, OrhanOrhanAktasBaum, KarlKarlBaumBerghoff, MartinMartinBerghoffBittner, StefanStefanBittnerChan, Andrew Hao-KuangAndrew Hao-KuangChanCzaplinski, AdamAdamCzaplinskiDeisenhammer, FlorianFlorianDeisenhammerDi Pauli, FranziskaFranziskaDi PauliDu Pasquier, RenaudRenaudDu PasquierEnzinger, ChristianChristianEnzingerFertl, ElisabethElisabethFertlGass, AchimAchimGassGehring, KlausKlausGehringGobbi, ClaudioClaudioGobbiGoebels, NorbertNorbertGoebelsGuger, MichaelMichaelGugerHaghikia, AidenAidenHaghikiaHartung, Hans-PeterHans-PeterHartungHeidenreich, FedorFedorHeidenreichHoffmann, OlafOlafHoffmannHunter, Zoë RZoë RHunterKallmann, BorisBorisKallmannKleinschnitz, ChristophChristophKleinschnitzKlotz, LuisaLuisaKlotzLeussink, VerenaVerenaLeussinkLeutmezer, FritzFritzLeutmezerLimmroth, VolkerVolkerLimmrothLünemann, Jan DJan DLünemannLutterotti, AndreasAndreasLutterottiMeuth, Sven GSven GMeuthMeyding-Lamadé, UtaUtaMeyding-LamadéPlatten, MichaelMichaelPlattenRieckmann, PeterPeterRieckmannSchmidt, StephanStephanSchmidtTumani, HayrettinHayrettinTumaniWeber, Martin SMartin SWeberWeber, FrankFrankWeberZettl, Uwe KUwe KZettlZiemssen, TjalfTjalfZiemssenZipp, FraukeFraukeZipp2024-09-022024-09-022021-08https://boris-portal.unibe.ch/handle/20.500.12422/42895Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, Switzerland).deAutoimmune-mediated disease Early therapeutic intervention Guideline Immunotherapy Treatment recommendation600 - Technology::610 - Medicine & health[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)article10.48350/1579613429714210.1007/s00115-021-01157-2